Abstract: The invention relates to the improvement of visual performance, particularly of visual performance in the darkness, by administration of a colorant that is capable of being incorporated into eye tissue and/or causing yellowing of eye tissue, especially carotenoids, such as lutein and zeaxanthin.

Abstract: An oil composition containing 25-hydroxy Vitamin D3 and an oil is provided. In addition an emulsion, a microencapsulated oil composition, and a feed premix composition each containing 25-hydroxy Vitamin D3 are provided. Methods of making an oil composition, a microencapsulated oil composition, and a feed premix containing 25-hydroxy Vitamin D3 are also provided.

Abstract: A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group consisting of a polar lipid which is not a stable vesicle former, a PEG, a raft former and a fusion protein is provided. The vesicle can further comprise a biomolecule, such as for example ATP. Methods of using the vesicle for delivery of biomolecules are also provided.

Abstract: The present invention provides a cosmetic having equal to or a higher antioxidant activity and moisture retaining property than the above-described conventional vitamin E derivatives. The cosmetic also has an excellent emulsifying ability and solubilizing ability and remarkably reduces a sticky feeling on the skin (in particular, the sticky feeling during drying after the application on the skin). That is, the cosmetic of the present invention containing a vitamin E derivative represented by the following formula (I) or a salt thereof. [In the formula, R1, R2, and R3 represent a hydrogen atom or a methyl group; R4 represents a C1-6 alkanoyl group, a C1-6 alkyl group, a SO3H group, a P(O)(OH)2 group, a CH2COOH group or a COCH2CH(SO3H)COOH group; EO represents an ethylene oxide group; BO represents a butylene oxide group; k and n independently represent any one of numbers 0 to 30; and m represents any one of numbers 1 to 30.

Abstract: This invention is directed to methods and compositions for the treatment of cardiovascular disorders. Specifically, the invention is directed to compositions comprising vitamin E, statins and/or glutathione peroxidase mimetics; methods of treating diabetic patients expressing the Hp-2-2 haptoglobin genotype; a method of inhibiting or suppressing a cardiovascular disorder in a diabetic subject, treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype; and methods of treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype.

Abstract: A Salvia hispanica L. derived seed oil extract composition of matter containing from 60-88% PUFAS in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-10% of C-18 mono-unsaturated fatty acid, 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form stable at room temperature of 12-24 months containing a mixture of selected antioxidants.

Abstract: Processes for obtaining aqueous dispersions comprising alcohols and acids obtained by hydrolysis of jojoba oil. Hydrolyzed jojoba oil products are treated by a process comprising neutralization of jojoba fatty acids with aliphatic organic amines dissolved in a co-solvent followed by the dispersion of both the neutralized fatty acids together with jojoba alcohols in an aqueous medium. The products obtained, generically named hydrolyzed jojoba oil (HJO), promote transdermal absorption and are useful vehicles for carrying a wide range of pharmaceutical and cosmetic compositions, including pharmaceutical and cosmetic compositions comprising either lipophilic or hydrophilic active principles. The HJO can also be used to produce a semisolid, self-emulsified jojoba oil (SEJO), obtained by emulsifying the HJO in jojoba oil.

Abstract: The present invention provides lipid compositions comprising linolenic acid (LA), alpha-linolenic acid (ALA), stearidonic acid (SDA) and gamma linolenic acid (GLA), said LA and ALA in a ratio of about less than 2:1 LA:ALA. The compositions find use in for improving, treating, or preventing a condition selected from the group consisting of: eczema, dry skin, flaky skin, pruritus, pyotraumatic dermatitis, furunculosis, dry paw pads, rough paw pads, chapped paw pads, paw pad durability, dry rhinarium, chapped rhinarium, split claws, brittle claws, rashes, hairless spots, hot spots, symmetrical lupoid onychodystrophy, skin ulceration, skin crusting, reddening of skin between toes, external ear infection, and nutritional dermatosis.

Abstract: The present invention provides antioxidant compositions comprising S-adenosylmethionine (SAMe), vitamin E and vitamin C and uses thereof for the treatment of liver injury and insulin resistance.

Abstract: The present invention relates to mechanically hemostatic body-absorbable compositions having a putty-like consistency comprising a finely powdered, carboxylic acid salt, a liquid block copolymer of ethylene oxide and propylene oxide, and a tocopherol.

Abstract: The present invention relates to the cosmetic use, by the oral route, of a combination of lycopene, of vitamin C, of vitamin E and of at least one polyphenol compound derived from pine bark as active ingredient intended for maintaining and/or restoring the biomechanical properties of keratinous materials, and notably of the skin.

Abstract: The field of invention relates to Vitamin C compositions, and in particular to Vitamin C compositions containing ascorbate-glucose transport enhancers. In at least one aspect, a composition is provided herein that includes ascorbate in an amount from about 0.1% by weight of actives to about 99.9% by weight of actives, and at least one ascorbate-glucose transport enhancer in an amount from about 0.01% by weight of actives to about 99.0% by weight of actives. In other aspects, methods of improving the transport of ascorbate into cells and tissues, and improving the ascorbate or antioxidant status of a person, are provided that include providing a composition comprising ascorbate and at least one ascorbate-glucose transport enhancer.

Abstract: A composition for treating, ameleliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death comprise a fatty acid component enriched for one or more activated fatty acids and a nutraceutically acceptable excipient. A method for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death includes administering a fatty acid component enriched for one or more activated fatty acids.

Abstract: A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is equal to or greater than a sum of the effect of the individual components. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, a donor antioxidant, a third antioxidant, and a vasodilator. A method of treating hearing loss includes the step of internally administering the composition including a biologically effective amount of the at least one scavenger of singlet oxygen, the donor antioxidant, the third antioxidant, and the vasodilator to a mammal within three days of trauma to a middle or inner ear of the mammal.

Abstract: Compounds of the general formula (formula I) in which the meanings of the substituents R1 to R6 are as indicated in claim 1, have renin-inhibiting properties and can be used as medicines.

Abstract: A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is greater than the effect of the individual components alone. The composition includes a biologically effective amount of vitamin E for inhibiting propagation of lipid peroxidation that contributes to hearing loss. The composition also includes a biologically effective amount of a salicylate for reducing hydroxyl radicals that contribute to hearing loss. A method of treating hearing loss includes the step of internally administering the composition, as described above, to a mammal within three days of trauma to a middle or inner ear of the mammal. In other words, the composition is effective even when administered as late as three days after trauma to a middle or inner ear of a mammal.

Abstract: It is described the use of L-carnitine, in combination with antioxidants such as vitamin E and inorganic elements such as manganese, zinc, sodium and potassium, for the preparation of a physiological supplement or medicament for opthalmic use, for the prevention or treatment of accomodative asthenopia.

Abstract: Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation.

Abstract: Gene panels, microarrays and biomarker panels relating to genes and gene products associated with age-related oxidative damage to skin, and transcriptional profiling-based methods for identification and evaluation of cosmetic agents for prevention, reversal, or reduction of oxidative damage to skin. Cosmetic agents and compositions comprising the cosmetic agents, capable of inducing nrf2-mediated activation of the antioxidant response element to increase expression of Phase 2 enzymes, methods for restoring optimal redox status to skin employing the agents, and methods for identifying and evaluating cosmetic agents acting via the nrf2-mediated mechanism.

Abstract: Activated fatty acids, topical compositions including activated fatty acids and methods for using activated fatty acids to treat a variety of diseases.

Abstract: The present invention provides a performance assay that measures the total antioxidant activity of a composition using oxygen uptake in contrast to prior art methods that measure antioxidant capacity by indirectly measuring degradation of a fluorescent compound by following the disappearance of fluorescence. Using the performance antioxidant assay of the present invention, an antioxidant composition having synergistic activity is provided by the present inventors that includes flavonoids such as the flavonol quercetin, mixed tocopherols or tocotrienols, grape skin extract, green tea extract and bush plum. The antioxidant activity of the present composition exceeds 6,000 micromoles Trolox equivalent units per gram using the present invention.

Abstract: Compositions for increased antioxidant potency of natural vitamin E (d-alpha-tocopherol), comprising alpha-, beta-, delta-, and gamma-forms of tocopherols and tocotrienols are disclosed. All of these compositions provide 400 International Units (IU), based on one mg of d-alpha-tocopherol provides 1.49 IU. These compositions showed antioxidant activities superior to natural d-alpha-tocopherol. These compositions are designed to provide protection of the cell membrane lipid layer, and protection against heart disease, cancer, and eye disease.

Abstract: This invention relates to compositions containing a retinoid and use of the compositions for treating skin conditions.

Abstract: Methods for the reduction or prevention of oxidative stress in an animal comprising administering to the animal an effective amount of a composition comprising astaxanthin and/or Vitamin E are described. Also described are compositions comprising astaxanthin and/or Vitamin E, the compositions being effective for the reduction or prevention of oxidative stress in an animal.

Abstract: The present invention relates to a new composition comprising substances that promote DNA repair, reduce body fat levels and increase lean body mass and that decrease wrinkle appearance and/or improvement in skin surface. In some aspects, the composition of the present invention include resveratrol, forskohlin and astaxanthin. In another aspect the composition of the present invention further comprises carboxy alkyl ester. The present invention also relates to a method of promoting internal health and external appearance in a subject in need, said method comprising administering to the subject a composition that promotes DNA repair, reduces body fat levels and increases lean body mass and that decreases wrinkle appearance and/or improvement in skin surface.

Abstract: The present invention relates to a dietary supplement composition made of: linolinic expeller pressed soybean oil in the range of 65%-85%, Omega 3 (18/12) fish oil 15%-35%, and 1%-20% alpha-tocopherol and a method to use this composition to supplement the diet of a domestic animal, such as a canine or an equine.

Abstract: The present invention relates to methods and immunonutritional compositions for preventing the impairment of the immune function during anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject undergoing anti-cancer therapy-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to anti-cancer therapy; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened by anti-cancer therapy.

Abstract: A general healing ointment for use on cracked lips, rashes, burns and the like is herein disclosed. The ointment is manufactured from an all natural blend of petroleum jelly, vitamin E cream and oil, cocoa butter, and pine pitch. It provides relief for a variety of ailments such as cracked skin, cold sores, rashes, acne, boils, and the like. It is readily absorbed by the skin and not visible to others, but won't dry out the skin afterwards.

Abstract: Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins are applied (A) directly to a genital wart in the form of a cream, ointment, paste or solution, (B) directly to the genital wart wherein such cream, ointment, paste or solution contains as an additional active ingredient a skin permeabilizing agent, (C) following electrosurgical resection or removal of the genital wart in such form of a cream, ointment, paste or solution, (D) following chemical resection or extirpation of the genital wart in such form, (E) following surgical resection or removal of the genital wart in such form, wherein said Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins both provide antiviral activity against multiple strains of human papilloma virus (HPV) and promote healing following resection polymers contained in a vehicle. Disclosed are the compositions, therapeutical kits containing such composition, methods of treatment using such composition, and methods of enhancing the stability of such composition.

Abstract: A formulation to deliver a full-spectrum of Vitamin E isomers for improved antioxidant capacity, bioavailability, dissolution and efficacy. The formulation includes dl-?-tocopheryl acetate or dl-?-tocopheryl succinate (synthetic Vitamin E), natural Vitamin E and mixed tocopherols, such as ?-, ?-, ?- and ?-tocopherol, as well as four isomers (?, ?, ? and ?) of tocotrienols. This formulation is designed to deliver at least 17-times the antioxidant capacity of synthetic Vitamin E (dl-?-tocopheryl acetate), and at least twice the antioxidant capacity of natural Vitamin E (d-?-tocopherol) as measured by oxygen radical absorbance capacity (ORAC) assay. The potent antioxidant capacity of this formula affords protection against oxidative damage of cell membranes, heart disease, cancer and eye and skin disease.

Abstract: Methods, compositions and kits are disclosed for infusing a hydrophobic catheter lock solution into an indwelling catheter. The combination of a tocopherol compound and at least one saturated mid-chain fatty acid provides a broad spectrum antimicrobial solution with optimal viscosity for effectively locking a catheter. The lock can effectively reduce or eliminate the risk of infection and prevents tainting the catheter, particularly clotting and thrombus in intravascular and extravascular catheters. The potential for this discovery is for maintaining or reestablishing the viability of an intravascular or extravascular catheter, as well as topical formulations for promoting healing.

Abstract: There is provided a method for preventing, alleviating symptoms or treating a skin condition comprising topically administering to the skin of a subject a cosmetic or pharmaceutical topical formulation comprising an effective skin-penetrating amount of one or more phosphate derivatives of one or more electron transfer agents.

Abstract: The disclosure provides compositions and methods for reducing the mutation rate of a virus, such as an RNA virus or a DNA virus, in a cell infected with the virus by, in one aspect, contacting the cell with an effective amount of an iron chelator or an antioxidant. Also provided are compositions and methods for enhancing the efficacy of an agent or a therapy directed at a virus.

Abstract: The use of the polyamine known as spermidine, i.e., N-(3-aminopropyl)tetraminethylenediamine, as an active principle in the preparation of a composition for pharmaceutical or dietetic use in man for combating hair loss is disclosed.

Abstract: The present invention relates to a chemical combination and method for increasing delivery of Coenzyme Q10. The chemical combination comprises Coenzyme Q10 mixed with at least one chemical. The at least one chemical includes cyclic monoterpene containing essential oil(s) that permit unprecedented levels of Coenzyme Q10 to be made available for delivery and absorption, increasing bioavailability, as well as overcoming the previous limits.

Abstract: The present invention provides a performance assay that measures the total antioxidant activity of a composition using oxygen uptake in contrast to prior art methods that measure antioxidant capacity by indirectly measuring degradation of a fluorescent compound by following the disappearance of fluorescence. Using the performance antioxidant assay of the present invention, an antioxidant composition having synergistic activity is provided by the present inventors that includes flavonoids such as the flavonol quercetin, mixed tocopherols or tocotrienols, grape skin extract, green tea extract and bush plum. The antioxidant activity of the present composition exceeds 6,000 micromoles Trolox equivalent units per gram using the present invention.

Abstract: The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-?-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, ?-tocopherol-9, and analogues thereof. The compounds of the present invention activate ER? and ER?, and express high estrogenic activity.

Abstract: Esters of tocotrienols having pharmacological activities pertinent to the treatment of breast cancer and other forms of cancer are disclosed herein. Among those compounds is (Z)-4-oxo-4-((R)-2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-yloxy)but-2-enoic acid. Tocotrienol esters were used to inhibit the growth and migration of +SA mammary epithelial cells and highly metastatic human breast cancer MDA-MB-231 cells respectively.

Abstract: The present invention provides compositions and methods for preventing or treating diseases and disorders, the composition comprising vitamin C, vitamin E, and at least one of an omega-3 fatty acid and an omega-6 fatty acid.

Abstract: Multivitamin/Multimineral supplements are provided for supplementing iron and desirable nutrients in the diet of mammals. The supplements include an iron-amino acid chelate, a form of iron more bioavailable than traditional iron salts. The supplements may further include a pharmaceutically accepted salt form of iron as well as other nutritional vitamins and minerals. The supplements are useful for providing iron for pregnant and lactating females as well as for persons suffering from anemia.

Abstract: Compositions for increased antioxidant potency of natural vitamin E(d-alpha-tocopherol), comprising alpha-, beta-, delta-, and gamma-forms of tocopherols and tocotrienols are disclosed. All of these compositions provide 400 International Units (IU), based on one mg of d-alpha-tocopherol provides 1.49 IU. These compositions showed antioxidant activities superior to natural d-alpha-tocopherol. These compositions are designed to provide protection of the cell membrane lipid layer, and protection against heart disease, cancer, and eye disease.

Abstract: A cosmetic composition has an association of at least three of the following substances with anti-free radical activity, selected from: 1) ebselen; or idebenone; or an association of the two; and 2) at least one substance with anti-free radical activity, or at least two substances with anti-free radical activity for obtaining said association of at least three substances with anti-free radical activity, said substance(s) being selected from: a) a substance of chemical formula (I) below: in which: R=a linear or branched, saturated or unsaturated C1-C16 hydrocarbon chain; and R1, R2 and R3 are identical or different and are a hydrogen atom or a methyl or methoxy radical, and its esters; b) an extract of Edelweiss; c) an extract of Emblica; and d) N-acetylcysteine. The anti-free radical activity is greatly improved.

Abstract: The eye is effectively treated by providing it with formulations including uncoated cationically charged microparticles of reversed cubic phase or reversed hexagonal phase material. The treatment methods are effective; for a variety of diseases and conditions including dry eye. The structure, charge and components of the microparticles in dispersion, with or without an active ingredient, provide mucoadhesion, layering, protection and prolonged duration of ophthalmic action.

Abstract: The disclosure relates to methods of treating or preventing neurological disorders using docosahexaenoic acid.

Abstract: This invention features methods for treating diseases associated with mutations in the CFTR gene by administering PPAR agonists, specifically PPAR?, PPAR?, and PPAR? agonists, PPAR inducers, and/or antioxidants. Also disclosed are screening methods for identifying therapeutically useful candidate compounds.

Abstract: A clear soft vegetarian dosage capsule comprising a first and second biphasic film. The first biphasic film has a plurality of first reservoirs and further comprises a polysaccharide, a seaweed extract, a rheology modifier, a buffer and a plasticizer. The second biphasic film has a plurality of second reservoirs having a formulation identical to the first film to ensure a sealing engagement. A dosage amount is disposed in each of the plurality of the reservoirs forming a plurality of filled reservoirs. The dosage amount is an emulsion, oil, hydrophilic liquid. The first film is extruded or overlaid with the second film allowing each of the plurality of second reservoirs to overlay the filled reservoirs and sealed with pressure and a fusion temperature slightly less than the melting point of the first and second films forming clear soft vegetarian dosage capsules that are blown dry, bonding moisture to the polysaccharide.

Abstract: The use of a composition containing vitamin E or a derivative thereof in a vehicle comprising a volatile siloxane for the control of arthropods, in particular ectoparasites such as lice, is described; the composition may be delivered by means of a spray delivery device or may be in the form of a hydrophobic gel.

Abstract: A companion pet diet meeting ordinary nutritional requirements for an aged pet and further comprising a sufficient amount of antioxidant or mixture thereof, to inhibit the deterioration of the mental capacity of an aged companion pet.

Abstract: A wipe article comprising a lotion composition comprising omega-6 fatty acid. A method of improving skin barrier function of vulvar skin comprising the step of contacting the vulvar skin with a wipe article, wherein omega-6 fatty acid is disposed on the surface of the wipe article.

Abstract: Methods of attenuating the toxic or medically undesirable effects of drugs and toxins in a human by administering to a human an injectable formulation comprised of a dispersion of particles comprised of reversed cubic or reversed hexagonal lyotropic liquid crystalline material. The particles absorb or adsorb or otherwise sequester and attenuate the effect of drugs and toxins, and may be used as a rescue or reversal agent, or as a prophylaxis. The invention is especially applicable in reversing adverse effects of local anesthetics inadvertently delivered systemically, and attenuating the therapeutic effects of general anesthetics in the course of treatment.